Skip to main content

Clinical Data Plans 3-for-2 Stock Split to Thump Chest, Draft New Investors

NEW YORK (GenomeWeb News) — Clinical Data last week said that its board has authorized a 3-for-2 stock split, which will be effected in the form of a stock dividend.
 
On Oct. 1, stockholders of record as on Sept. 24 will receive one new share for every two shares they hold, the company said in a statement.
 
CEO Drew Fromkin said the split “reflects the confidence we have in the prospects of our company,” and is “an opportunity to broaden our base of investors by making our stock more accessible while improving its liquidity.”
 
Shares in the company briefly reached $35.08 last Friday, or around 20 percent higher than the day Clinical Data declared the split two days earlier. They were down at $31.82 in mid-afternoon, which is still 7.5 percent better than the closing price Sept.12.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.